Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
J Diabetes Investig. 2018 Sep;9(5):1025-1032. doi: 10.1111/jdi.12802. Epub 2018 Mar 12.
AIMS/INTRODUCTION: Complete mechanisms of renoprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors have not been elucidated yet. Mitochondrial biogenesis is regulated by membrane GTPases, such as optic atrophy factor 1 and mitofusion 2. Here, we investigated whether SGLT2 inhibition in mice fed with a high-fat diet (HFD) improved mitochondrial morphology and restored mitochondrial biogenesis-related molecules.
Mice were fed a control diet or HFD with or without ipragliflozin treatment. After 16 weeks, the kidneys were taken out and utilized for the analysis.
HFD-fed mice treated with ipragliflozin showed increased caloric intake and ate more food than the control HFD-fed mice. Body and kidney weights, and blood glucose levels were not altered by ipragliflozin treatment in HFD-fed mice. Histological analysis showed that, compared with control mice, HFD-fed mice displayed tubular vacuolation, dilatation and epithelial cell detachment; ipragliflozin ameliorated these alterations. Furthermore, ultrastructural analysis showed that the tubule mitochondria of HFD-fed mice exhibited significant damage. Again, ipragliflozin reversed the damage to a normal state, and restored optic atrophy factor 1 and mitofusion 2 levels in HFD-fed mice. Increased urine 8-hydroxydeoxyguanosine levels in HFD-fed mice were suppressed by ipragliflozin as well. In vitro experiments using HK-2 cells revealed that either high glucose or high palmitate suppressed optic atrophy factor 1 and mitofusion 2 levels. Suppression of SGLT2 by a specific small interfering ribonucleic acid or ipragliflozin restored these GTPase levels to their normal values.
SGLT2 inhibition might act directly on tubular cells and protect kidney tubular cells from mitochondrial damage by metabolic insults regardless of blood glucose levels or improvement in bodyweight reduction.
目的/引言:钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂的肾保护作用的完整机制尚未阐明。线粒体生物发生受膜 GTP 酶(如视神经萎缩因子 1 和线粒体融合 2)调节。在这里,我们研究了高脂肪饮食(HFD)喂养的小鼠中 SGLT2 抑制是否改善了线粒体形态并恢复了与线粒体生物发生相关的分子。
将小鼠喂以对照饮食或 HFD,并接受或不接受伊格列净治疗。16 周后,取出肾脏进行分析。
与对照 HFD 喂养的小鼠相比,接受伊格列净治疗的 HFD 喂养的小鼠表现出更高的热量摄入和更多的食物摄入。HFD 喂养的小鼠中,伊格列净治疗并未改变体重和肾脏重量以及血糖水平。与对照小鼠相比,HFD 喂养的小鼠表现出肾小管空泡化、扩张和上皮细胞脱落;伊格列净改善了这些改变。此外,超微结构分析显示 HFD 喂养的小鼠的肾小管线粒体显示出明显的损伤。同样,伊格列净将损伤逆转至正常状态,并恢复了 HFD 喂养的小鼠中的视神经萎缩因子 1 和线粒体融合 2 水平。伊格列净还抑制了 HFD 喂养的小鼠尿液 8-羟基脱氧鸟苷水平的升高。HK-2 细胞的体外实验表明,高葡萄糖或高棕榈酸均抑制了视神经萎缩因子 1 和线粒体融合 2 的水平。用特异性小干扰核糖核酸或伊格列净抑制 SGLT2 将这些 GTP 酶水平恢复至正常水平。
SGLT2 抑制可能直接作用于肾小管细胞,并通过代谢应激保护肾小管细胞免受线粒体损伤,而与血糖水平或体重减轻的改善无关。